Optiver Holding
HAE icon

Optiver Holding’s Haemonetics HAE Stock Holding History

Optiver Holding’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.5K Buy
287
+127
+79% +$8.16K ﹤0.01% 1493
2026
Q1 		$9.02K Sell
160
-126
-44% -$8.21K ﹤0.01% 1241
2025
Q4 		$22.9K Sell
286
-86
-23% -$5.78K ﹤0.01% 1006
2025
Q3 		$18.1K Sell
372
-8
-2% -$495 ﹤0.01% 997
2025
Q2 		$28.4K Buy
380
+8
+2% +$530 ﹤0.01% 740
2025
Q1 		$23.6K Buy
+372
New +$25.3K ﹤0.01% 654

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Optiver Holding's HAE Position: Q2 2026 in Review

Optiver Holding increased its Haemonetics (HAE) stake by 79% in Q2 2026, buying an estimated $8.16K and bringing the position to 287 shares worth $21.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1493.

Optiver Holding first reported a position in HAE in Q1 2025 and has held it in 6 quarters since. The position peaked at $28.4K in Q2 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Optiver Holding held 287 shares of Haemonetics worth $21.5K as of Q2 2026.
  • Optiver Holding bought 127 Haemonetics shares in Q2 2026, an estimated $8.16K.
  • Haemonetics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #1493 holding.
  • Optiver Holding first reported a position in Haemonetics in Q1 2025 and has held it in 6 quarters since.
  • Optiver Holding's Haemonetics position peaked at $28.4K in Q2 2025.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.